Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Neurology ; 80(10): 882-9, 2013 Mar 05.
Artigo em Inglês | MEDLINE | ID: mdl-23325908

RESUMO

OBJECTIVES: Postinfectious neurologic syndromes (PINSs) of the CNS include heterogeneous disorders, sometimes relapsing. In this study, we aimed to a) describe the spectrum of PINSs; b) define predictors of outcome in PINSs; and c) assess the clinical/paraclinical features that help differentiate PINSs from multiple sclerosis (MS). METHODS: In this prospective cohort study, adult inpatients with PINSs underwent extensive diagnostic assessment and therapeutic protocols at inclusion and during a minimum 2-year follow-up. We compared them with newly diagnosed, treatment-naive patients with MS, also prospectively recruited. RESULTS: The study sample comprised 176 patients with PINSs aged 59.9 ± 17.25 years (range: 18-80 years) divided into 2 groups: group 1 (CNS syndromes, 64%)-encephalitis, encephalomyelitis, or myelitis; and group 2 (CNS + peripheral nervous system [PNS] syndromes, 36%)-encephalomyeloradiculoneuritis or myeloradiculoneuritis. We observed the patients for 24 to 170 months (median 69 months). Relapses, almost invariably involving the spinal cord, occurred in 30.5%. PNS involvement was an independent risk factor for relapses (hazard ratio 2.8). The outcome was poor in 43% of patients; risk factors included older age, greater neurologic disability at onset, higher serum-CSF albumin percentage transfer, myelitis, and PNS involvement. Steroid resistance occurred in 30% of the patients, half of whom responded favorably to IV immunoglobulins. Compared with MS, PINSs were characterized by older age, lower tendency to relapse, and distinct CSF findings. CONCLUSIONS: The category of PINSs should be revised: most of the clinical variants have a poor prognosis and are not readily classifiable on the basis of current knowledge. PNS involvement has a critical role in relapses, which seem to affect the spine only.


Assuntos
Infecções/complicações , Doenças do Sistema Nervoso/diagnóstico , Doenças do Sistema Nervoso/etiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Diagnóstico Diferencial , Encefalomielite Aguda Disseminada/diagnóstico , Encefalomielite Aguda Disseminada/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/diagnóstico , Mielite Transversa/diagnóstico , Mielite Transversa/etiologia , Síndrome , Vacinas/efeitos adversos , Adulto Jovem
2.
J Neurol Sci ; 303(1-2): 139-41, 2011 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-21296362

RESUMO

We report on the first patient with a relapsing, anti-aquaporin-4 (AQP-4) antibody-positive, longitudinally extensive transverse myelitis (LETM) who developed systemic sclerosis (SSc). A 62-year-old woman, who presented with bilateral, distal lower limb and perineal numbness, developed clinical manifestations and paraclinical features of SSc. Spinal cord imaging revealed lesions that were consistent with LETM. Patient's serum was positive for neuromyelitis optica (NMO)-IgG/AQP-4 antibodies. High-dose intravenous corticosteroids improved the neurological symptoms. The present case expands the list of autoimmune systemic diseases that occur in neuromyelitis optica spectrum disorders associated with NMO-IgG/AQP-4 antibodies.


Assuntos
Aquaporina 4/imunologia , Autoanticorpos/análise , Mielite Transversa/complicações , Mielite Transversa/imunologia , Escleroderma Sistêmico/etiologia , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Encéfalo/patologia , Doenças do Nervo Facial/complicações , Doenças do Nervo Facial/patologia , Feminino , Humanos , Injeções Intravenosas , Imageamento por Ressonância Magnética , Metilprednisolona/administração & dosagem , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Debilidade Muscular/complicações , Neuromielite Óptica/complicações , Neuromielite Óptica/imunologia , Prednisolona/administração & dosagem , Prednisolona/uso terapêutico , Medula Espinal/patologia
3.
J Neurol Sci ; 290(1-2): 148-9, 2010 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-20056249

RESUMO

OBJECTIVE: To report clinical and pathological findings of a patient with late onset insulin-dependent diabetes mellitus (IDDM), progressive cerebellar ataxia (PCA) and hepatocellular carcinoma (HCC). PATIENT: A 64-year-old woman, with a long lasting IDDM, progressively developed a severe cerebellar syndrome and died 2 years after the onset of the symptoms for a systemic infection. Autoantibodies to antigastric parietal cell and anti-pancreatic islet cell resulted positive. Autopsy showed a selective loss of Purkinje cells in the cerebellum, with an increase of Bergmann glia and variable microglial proliferation; furthermore, it disclosed an HCC. GAD-Abs were detected both in serum and CSF. CONCLUSIONS: Clinical and experimental reports suggest a possible role of neoplastic cells in producing GAD-Abs. We postulate, in our case, that HCC could have been responsible for an overproduction of GAD-Abs, leading to the onset of PCA. Thus, GAD-Abs could be considered as a paraneoplastic marker in a subgroup of patients with PCA.


Assuntos
Carcinoma Hepatocelular/fisiopatologia , Ataxia Cerebelar/fisiopatologia , Diabetes Mellitus Tipo 1/fisiopatologia , Glutamato Descarboxilase/imunologia , Neoplasias Hepáticas/fisiopatologia , Poliendocrinopatias Autoimunes/fisiopatologia , Autoanticorpos/análise , Autoanticorpos/sangue , Autoanticorpos/imunologia , Carcinoma Hepatocelular/imunologia , Carcinoma Hepatocelular/patologia , Ataxia Cerebelar/imunologia , Ataxia Cerebelar/patologia , Cerebelo/imunologia , Cerebelo/patologia , Cerebelo/fisiopatologia , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 1/patologia , Progressão da Doença , Evolução Fatal , Feminino , Gliose/imunologia , Gliose/patologia , Gliose/fisiopatologia , Humanos , Ilhotas Pancreáticas/imunologia , Ilhotas Pancreáticas/patologia , Neoplasias Hepáticas/imunologia , Neoplasias Hepáticas/patologia , Pessoa de Meia-Idade , Células Parietais Gástricas/imunologia , Células Parietais Gástricas/patologia , Poliendocrinopatias Autoimunes/complicações , Poliendocrinopatias Autoimunes/patologia , Células de Purkinje/imunologia , Células de Purkinje/patologia , Sepse/imunologia , Sepse/patologia , Sepse/fisiopatologia
4.
Neurol Sci ; 29 Suppl 2: S247-9, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18690507

RESUMO

Fatigue is a psychophysiological state that acts on the subject's motivation to engage in and/or to continue strenuous physical or cognitive activities. In various pathological conditions fatigue seems to lose this homeostatic function and presents itself as a symptom. The pathophysiology of fatigue is complex and includes neurological (central and peripheral) dysfunction, and altered neurotransmitter, cytokine, and hormonal settings. Treatment interventions are generally based on a sequential approach including treatment of comorbid factors, nonpharmacological treatments, and drugs.


Assuntos
Sistema Nervoso Central/fisiopatologia , Síndrome de Fadiga Crônica/fisiopatologia , Síndrome de Fadiga Crônica/terapia , Homeostase/imunologia , Sistema Nervoso Central/imunologia , Estimulantes do Sistema Nervoso Central/uso terapêutico , Terapia Cognitivo-Comportamental/normas , Citocinas/imunologia , Citocinas/metabolismo , Diagnóstico Diferencial , Terapia por Exercício/normas , Síndrome de Fadiga Crônica/imunologia , Humanos , Neurotransmissores/imunologia , Neurotransmissores/metabolismo
5.
Funct Neurol ; 17(3): 137-44, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12549719

RESUMO

The authors developed two scales to be adopted for the evaluation of myasthenia gravis (MG) patients. The first scale (MG impairment scale) is based on objective patient evaluation and on patients' responses to standardized questions relating to the functioning of specific muscle groups. It consists of 13 items exploring strength and 10 items exploring fatigability. The second scale (MG disability scale) evaluates disability in those everyday activities that are often impaired in MG patients. Test-retest reliability of each item and of the global score (sum of single item scores) was assessed by the weighted K statistic and by the intraclass correlation coefficient. Reliability was invariably 'substantial', and for single items 'almost perfect' for the MG impairment scale, and invariably 'almost perfect' for the MG disability scale. The internal structure of the MG impairment scale was explored by means of the principal component analysis. This analysis resulted in three main (rotated) factors, which loaded respectively onto 'ocular', 'spinal' and 'bulbar' functions. For these factors, we report factor score coefficients that can be used to compute single patients' scores, which in turn may be used in further analyses, particularly for follow-up studies. We also report the results of an analysis of the correlations between the two scales. The MG impairment and the MG disability scales are proposed for application in both clinical and research settings.


Assuntos
Atividades Cotidianas/classificação , Avaliação da Deficiência , Miastenia Gravis/diagnóstico , Adolescente , Adulto , Idoso , Feminino , Humanos , Contração Isométrica/fisiologia , Masculino , Pessoa de Meia-Idade , Fadiga Muscular/fisiologia , Músculo Esquelético/inervação , Miastenia Gravis/classificação , Miastenia Gravis/fisiopatologia , Exame Neurológico/estatística & dados numéricos , Variações Dependentes do Observador , Reprodutibilidade dos Testes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA